{"ticker": {"uuid": "e168b66b-daff-42f0-bf29-b52d95ab1ba2", "symbol": "ZYBT", "name": "Zhengye Biotechnology Holding Limited Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Zhengye Biotechnology Holding Ltd (ZYBT), focusing on its support, resistance, indicators, and moving averages. According to the analysis, ZYBT currently exhibits a strong \"Sell\" signal based on various technical indicators and moving", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/technical", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:12", "published_display": "18 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5XMFdzM1NYUGNCM0MzV3FsU1N0bzRWZzdLWnpYMnZjUXpwbXpKbU1wM0xLbC0ybHhXTU9GS1RqcF95anpXSF9SSTJybTJqaHdjMmhpYjI3M2g5MFQta1VUc2FUZHNUX3VoLVoxc2VNQS0?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T14:34:10+00:00", "published_display": "17 Jun 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Zhengye Biotechnology Holding Ltd (ZYBT) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years and shows no record of stock splits. The page also inc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T12:10:25", "published_display": "17 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE16WmE2c0tlQ1MzQlNYeTRJZkJPai11b1hCdmZvZUpMTFFFQmN2TFBmMXBNOUtGVTRHaE00Tm5GTGhPMVowVWV0TFFHWXVNNldXbHRGX3VPRktoWURwMGpuMWQ3bklEcmpiOXFYOGRZdw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T10:50:52+00:00", "published_display": "17 Jun 2026 10:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTFBwMU9OX0ZGbDl2Z3BTT3RQSTB0ekJpak0yWnpCVTZVa3VkcURRaWh5anJNS1J2RGQ5MnYwRk1UZGUzOHdTOWZ3M1V3NExlNDZVdW5BMi1SenBYaUFoQUtybE5obkxWcEt2YnhxWTJEamV3RWE3T1dv?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T10:49:47+00:00", "published_display": "17 Jun 2026 10:49", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE12bXFGYWZ3Zi1ab0xIX1lEMjdaZ0dyZjM1WGxZaU5IZFJ6eVk0R0I0c0ttSWx6WG5ReEpMZ0NZbTdWT0Z0b0w4ZHo4R0w1SVdlbkF2MkRiU3Q5RGF2eU5jdjFnMkVmaS0xNURHQmJNdmtrcFlHc25MMHRn?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T10:19:39+00:00", "published_display": "17 Jun 2026 10:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Zhengye Biotechnology Holding Ltd (ZYBT), noting that relevant data for P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The stock is currently trading at $0.809, down 3.98%, with a market cap of 38.34M.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T11:10:40", "published_display": "17 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Institutional Confidence", "summary": "The article details the institutional confidence in Zhengye Biotechnology Holding Ltd (ZYBT) by listing its institutional shareholders and their recent activity. Key shareholders include Han (Zhenfa), XTX Markets LLC, Winton Capital Management Ltd., and Citadel Advisors LLC, with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:40", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd", "summary": "This article provides a detailed revenue breakdown for Zhengye Biotechnology Holding Ltd (ZYBT) for fiscal year 2024. It highlights the company's primary revenue sources, with swine vaccines accounting for the largest proportion at 84.67%, followed by poultry vaccines and other v", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:40", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology receives Nasdaq bid price deficiency notice", "summary": "Zhengye Biotechnology (NASDAQ:ZYBT) has received a notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share, with its stock trading significantly lower. The company has 180 calendar days to regain compliance, potentially considering a reverse sh", "url": "https://m.uk.investing.com/news/stock-market-news/zhengye-biotechnology-receives-nasdaq-bid-price-deficiency-notice-93CH-4714641?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-05T21:39:27", "published_display": "05 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology receives Nasdaq bid price deficiency notice By Investing.com", "summary": "Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) has received a Nasdaq deficiency notice for failing to meet the minimum bid price requirement of $1.00 per share. The company has 180 days to regain compliance by achieving a closing bid price of at least $1.00 for ten consecuti", "url": "https://m.au.investing.com/news/stock-market-news/zhengye-biotechnology-receives-nasdaq-bid-price-deficiency-notice-93CH-4472728?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-05T19:09:51", "published_display": "05 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotech's Nasdaq Lifeline: A 180-Day Race Against Financial Reality", "summary": "Zhengye Biotech (Nasdaq: ZYBT) has received a Nasdaq deficiency notice due to its stock failing to maintain the $1.00 minimum bid price, giving it until November 25, 2026, to regain compliance. The company faces significant financial challenges, including an 87% stock drop, a 37.", "url": "https://briefglance.com/articles/zhengye-biotechs-nasdaq-lifeline-a-180-day-race-against-financial-reality", "source_name": "BriefGlance", "published_at": "2026-06-05T09:11:10", "published_display": "05 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Receives Nasdaq Letter for Minimum Bid Price Deficiency", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/zhengye-biotechnology-receives-nasdaq-letter-205504062.html", "source_name": "MT Newswires", "published_at": "2026-06-04T20:55:04+00:00", "published_display": "04 Jun 2026 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotech has 6 months to lift stock back above $1", "summary": "Zhengye Biotechnology (ZYBT) received a Nasdaq notice on May 29, 2026, for failing to meet the US$1.00 minimum bid price requirement for 30 consecutive business days. The company has until November 25, 2026, to regain compliance by having its stock close at or above US$1.00 for a", "url": "https://www.stocktitan.net/news/ZYBT/zhengye-biotechnology-holding-limited-receives-nasdaq-notification-liify8zbpl9h.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:05:04", "published_display": "04 Jun 2026 20:05", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency", "summary": "Zhengye Biotechnology Holding Limited (ZYBT) announced it received a Nasdaq notification for not meeting the minimum bid price requirement of US$1.00 per share. The company has 180 calendar days, until November 25, 2026, to regain compliance by maintaining a closing bid price of ", "url": "https://sg.finance.yahoo.com/news/zhengye-biotechnology-holding-limited-receives-200500447.html", "source_name": "Market source", "published_at": "2026-06-04T20:05:03", "published_display": "04 Jun 2026 20:05", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Receives Nasdaq Non-Compliance Notification Regarding Minimum Bid Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNQ0UzdlNmWFBZckNzVVI4WXFFWmhXTm1xSWhjbzdDVlBSX0JxRzdNQ0VfWXBZZ0VBaU9mWVJVS3BXUVZZMks2N0ZSb0UzSm80d0dfY1hTbFNrYmtmZkJHN1ZIRklTMUpHMU9IQkJ5ZV9fdklWM0tKcFJhSEVWbjc4MnZybF9zVGxaWEhlRVhjVldsRE1PNFdwOUUtRDd6d2l2QmM2Ui03Y1l3aldfV0lpZDJLaDY4ZlU1TUl6V0FpNkMtZU9UcVd0cWdVQWVNQmFCYjdJQlZYYkpCdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYBT Stock Price, Quote & Chart | ZHENGYE BIOTECHNOLOGY-A (NASDAQ:ZYBT)", "summary": "This article provides a detailed overview of ZHENGYE BIOTECHNOLOGY-A (NASDAQ: ZYBT) stock, including its current price, performance metrics, and key statistics like market cap and EPS. It also presents ChartMill's technical and fundamental analysis ratings, highlighting the compa", "url": "https://www.chartmill.com/stock/quote/ZYBT/profile", "source_name": "ChartMill", "published_at": "2026-05-17T18:39:02", "published_display": "17 May 2026 18:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "This page provides an overview of Zhengye Biotechnology Holding Ltd (ZYBT) on TradingKey. It details the stock's current price, market cap, and offers sections for financials, discussions, and analysis. The content also highlights TradingKey's various tools, news, and educational", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/comments", "source_name": "TradingKey", "published_at": "2026-05-12T02:39:13", "published_display": "12 May 2026 02:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results", "summary": "Zhengye Biotechnology Holding Limited announced its financial results for fiscal year 2025, reporting a net loss of RMB83.0 million, compared to a net income of RMB13.5 million in 2024. This downturn was primarily due to a challenging hog market and government policies impacting ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zhengye-biotechnology-holding-limited-announces-203000334.html", "source_name": "Market source", "published_at": "2026-04-29T20:10:06", "published_display": "29 Apr 2026 20:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China hog slump hits Zhengye as vaccine maker posts annual loss", "summary": "Zhengye Biotechnology (Nasdaq: ZYBT) announced a 37.6% decrease in total revenue for fiscal year 2025, reaching RMB116.4 million ($16.6 million), and reported a net loss of RMB83.0 million ($11.9 million). This decline was primarily attributed to a downturn in China's hog market ", "url": "https://www.stocktitan.net/news/ZYBT/zhengye-biotechnology-holding-limited-announces-fiscal-year-2025-jlrqrpqnxug3.html", "source_name": "Stock Titan", "published_at": "2026-04-28T20:09:58", "published_display": "28 Apr 2026 20:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYBT Price Today: Zhengye Biotechnology Holding Limited Stock Price, Quote & Chart | MEXC", "summary": "Zhengye Biotechnology Holding Limited (ZYBT) is currently trading at $0.91, down from its previous close of $0.92. The stock has seen a +7.06% return over the past month but a significant -93.57% decline over the last 12 months, indicating weak performance. The company specialize", "url": "https://www.mexc.co/stocks/zybt", "source_name": "MEXC Exchange", "published_at": "2026-04-25T16:10:24", "published_display": "25 Apr 2026 16:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026", "summary": "Zhengye Biotechnology Holding Limited has implemented a dual-class share structure, effective April 7, 2026, introducing Class A and Class B ordinary shares with different voting rights. This restructuring, approved by shareholders, aims to enhance corporate governance and capita", "url": "https://www.quiverquant.com/news/Zhengye+Biotechnology+Holding+Limited+Announces+Implementation+of+Dual-Class+Share+Structure+Effective+April+7%2C+2026", "source_name": "Quiver Quantitative", "published_at": "2026-04-06T13:30:00", "published_display": "06 Apr 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure", "summary": "Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced the implementation of a dual-class share structure, effective April 7, 2026. The new structure introduces Class A ordinary shares with one vote each and Class B ordinary shares with twenty votes each, with Class B sha", "url": "https://www.globenewswire.com/news-release/2026/04/06/3268492/0/en/Zhengye-Biotechnology-Holding-Limited-Announces-Implementation-of-Dual-Class-Share-Structure.html", "source_name": "GlobeNewswire", "published_at": "2026-04-06T13:10:31", "published_display": "06 Apr 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye's new share classes give some holders 20 votes each", "summary": "Zhengye Biotechnology Holding Limited (ZYBT) has implemented a dual-class share structure, effective April 7, 2026, following shareholder approval on March 24, 2026. This reclassifies the authorized capital into 1.9 billion Class A ordinary shares, each carrying one vote, and 100", "url": "https://www.stocktitan.net/news/ZYBT/zhengye-biotechnology-holding-limited-announces-implementation-of-kxejeuix38pk.html", "source_name": "Stock Titan", "published_at": "2026-04-06T13:10:31", "published_display": "06 Apr 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM", "summary": "Zhengye Biotechnology Holding Ltd. (ZYBT) held its Annual General Meeting on March 24, 2026, where shareholders approved significant changes to the company's governance and share structure. These changes involved the election of new directors, re-election of existing ones, a shar", "url": "https://www.tipranks.com/news/company-announcements/zhengye-biotechnology-shareholders-approve-governance-and-share-structure-changes-at-march-24-agm", "source_name": "TipRanks", "published_at": "2026-03-25T10:39:37", "published_display": "25 Mar 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Zhengye Biotechnology (ZYBT.US)$ still hodl some for moon", "summary": "A moomoo Community member, MsNoFomoTrade, shared a post regarding Zhengye Biotechnology (ZYBT.US), indicating they are still holding the stock with an optimistic outlook for future gains. The brief post is part of a discussion within the moomoo community platform.", "url": "https://www.moomoo.com/community/feed/zhengye-biotechnology-zybt-us-still-hodl-for-moon-116278005530630?chain_id=Name1K9-3FXPhg.1l0puc0&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A57%2C%22f%22%3A%22www.moomoo.com%2Fstock%2FDLO-US%22%7D", "source_name": "Moomoo", "published_at": "2026-03-23T15:39:11", "published_display": "23 Mar 2026 15:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Announces Resignation of Wenbin Wang as Independent Director, Member of Committees, and Chairperson of the Compensation Committee, Effective February 18, 2026", "summary": "Zhengye Biotechnology Holding Limited announced that Wenbin Wang resigned as an independent director, a member of the Audit, Compensation, and Nominating and Corporate Governance Committees, and chairperson of the Compensation Committee, effective February 18, 2026. Wang's resign", "url": "https://www.marketscreener.com/news/zhengye-biotechnology-holding-limited-announces-resignation-of-wenbin-wang-as-independent-director-ce7e5cd8d980ff24", "source_name": "www.marketscreener.com", "published_at": "2026-02-24T10:51:40", "published_display": "24 Feb 2026 10:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM", "summary": "Zhengye Biotechnology Holding Ltd. announced that independent director Wenbin Wang resigned on February 18, 2026, due to personal reasons, leaving the company temporarily non-compliant with Nasdaq's majority independent director rule. The company plans to appoint a replacement at", "url": "https://www.tipranks.com/news/company-announcements/zhengye-biotechnology-director-resigns-nasdaq-independence-deficiency-to-be-addressed-at-march-agm", "source_name": "TipRanks", "published_at": "2026-02-23T21:30:11", "published_display": "23 Feb 2026 21:30", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYBT Should I Buy", "summary": "An analysis of Zhengye Biotechnology Holding Ltd (ZYBT) indicates it is not a strong buy for long-term beginner investors. Technical indicators show a bearish trend with weakening momentum and no positive catalysts or significant trading signals. The stock is trading below its pi", "url": "https://intellectia.ai/en/stock/ZYBT/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-02-23T11:51:18", "published_display": "23 Feb 2026 11:51", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Issues 2026 Chairman\u2019s Letter to Shareholders", "summary": "Zhengye Biotechnology Holding Limited's Chairman, Zhenfa Han, issued a letter to shareholders detailing the company's achievements in 2025 and strategic priorities for 2026. The letter highlights R&D innovation, regulatory milestones, international market expansion, enhanced prod", "url": "https://www.globenewswire.com/news-release/2026/02/10/3235307/0/en/Zhengye-Biotechnology-Holding-Limited-Issues-2026-Chairman-s-Letter-to-Shareholders.html", "source_name": "GlobeNewswire", "published_at": "2026-02-10T13:58:26", "published_display": "10 Feb 2026 13:58", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter", "summary": "Zhengye Biotechnology Holding Limited, a veterinary vaccine manufacturer, released a shareholder letter highlighting its 2025 achievements and outlining its strategic plan for 2026. The company reported significant milestones in R&D, regulatory approvals, international market exp", "url": "https://www.quiverquant.com/news/Zhengye+Biotechnology+Holding+Limited+Highlights+2025+Achievements+and+2026+Strategic+Plan+in+Shareholder+Letter", "source_name": "Quiver Quantitative", "published_at": "2026-02-10T13:44:00", "published_display": "10 Feb 2026 13:44", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Sees Large Decline in Short Interest", "summary": "Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) experienced a significant 33.1% decrease in short interest in December, reducing the total shorted shares to 30,788. Several hedge funds, including Jane Street and Invesco, established new positions in the company despite its cu", "url": "https://www.marketbeat.com/instant-alerts/zhengye-biotechnology-holding-limited-nasdaqzybt-sees-large-decline-in-short-interest-2025-12-29/", "source_name": "MarketBeat", "published_at": "2025-12-29T17:08:52", "published_display": "29 Dec 2025 17:08", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) May Have Run Too Fast Too Soon With Recent 26% Price Plummet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSVg1aUU0eGdnYTBQaFRZcEhtdjNKOS1yb0xkVHdnSHpCQ3BzZUlPV2NfeXZrbnQ3X0F4MktFcW0yQzVvbEpscEp5Nm1Mak50VWRZQXpHeGZDOVptdWd3a1drTzFOb2NvNUVjSHN5VjU5QWNwREx4bE1wWk5MNmxvUzlpLXRPRWc0cExVZE4wSG1iYzBkcW5mb0pYOGdOaUREUjZUQndBZnk2SXc?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) 26% Share Price Surge Not Quite Adding Up", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotech Earnings: Revenue Falls 12% as Company Pivots to Pet Vaccines with Exclusive Drug Approvals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUm05LU9FRW5lSEU5WHRlNDV6VWFYSG9XRzA4c2pXczBBRDNfYmcxdy1XRmQ2eGxyRzNOX0xDWEZMSGFBdkl2RnU1NUNGWlI4TG5xYXF5Q3FkWHpTWjR0aXlEOHhWeVFpT052TEVhaU9rLUcyMlhVb0hkSm55RnhUOFNMUmdCeWNaQ2FDNlM0ZlZmd3BlenNLblUyMU1rd1MxaC1MdU9CaTZqVThNN28yQ0dPRWZxeW1McXp3?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-03T07:00:00+00:00", "published_display": "03 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYBT Stock Price and Chart \u2014 NASDAQ:ZYBT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE84U1k3X0pLUFFLQ250dTVWVjRYclZPT1R3LThaNXY3ZGF5Tm5taGdLNGJpYUFQU2dzZWNQTXBNdl90REZnZkhGYXhJd0dSa3Z5cExQWW5RV1l5TWpS?oc=5", "source_name": "TradingView", "published_at": "2025-01-07T16:38:47+00:00", "published_display": "07 Jan 2025 16:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Zhengye Biotechnology Holding Ltd (ZYBT), focusing on its support, resistance, indicators, and moving averages. According to the analysis, ZYBT currently exhibits a strong \"Sell\" signal based on various technical indicators and moving", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/technical", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:12", "published_display": "18 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5XMFdzM1NYUGNCM0MzV3FsU1N0bzRWZzdLWnpYMnZjUXpwbXpKbU1wM0xLbC0ybHhXTU9GS1RqcF95anpXSF9SSTJybTJqaHdjMmhpYjI3M2g5MFQta1VUc2FUZHNUX3VoLVoxc2VNQS0?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T14:34:10+00:00", "published_display": "17 Jun 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Zhengye Biotechnology Holding Ltd (ZYBT) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years and shows no record of stock splits. The page also inc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T12:10:25", "published_display": "17 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE16WmE2c0tlQ1MzQlNYeTRJZkJPai11b1hCdmZvZUpMTFFFQmN2TFBmMXBNOUtGVTRHaE00Tm5GTGhPMVowVWV0TFFHWXVNNldXbHRGX3VPRktoWURwMGpuMWQ3bklEcmpiOXFYOGRZdw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T10:50:52+00:00", "published_display": "17 Jun 2026 10:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTFBwMU9OX0ZGbDl2Z3BTT3RQSTB0ekJpak0yWnpCVTZVa3VkcURRaWh5anJNS1J2RGQ5MnYwRk1UZGUzOHdTOWZ3M1V3NExlNDZVdW5BMi1SenBYaUFoQUtybE5obkxWcEt2YnhxWTJEamV3RWE3T1dv?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T10:49:47+00:00", "published_display": "17 Jun 2026 10:49", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE12bXFGYWZ3Zi1ab0xIX1lEMjdaZ0dyZjM1WGxZaU5IZFJ6eVk0R0I0c0ttSWx6WG5ReEpMZ0NZbTdWT0Z0b0w4ZHo4R0w1SVdlbkF2MkRiU3Q5RGF2eU5jdjFnMkVmaS0xNURHQmJNdmtrcFlHc25MMHRn?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T10:19:39+00:00", "published_display": "17 Jun 2026 10:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Zhengye Biotechnology Holding Ltd (ZYBT), noting that relevant data for P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The stock is currently trading at $0.809, down 3.98%, with a market cap of 38.34M.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T11:10:40", "published_display": "17 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd (ZYBT) Institutional Confidence", "summary": "The article details the institutional confidence in Zhengye Biotechnology Holding Ltd (ZYBT) by listing its institutional shareholders and their recent activity. Key shareholders include Han (Zhenfa), XTX Markets LLC, Winton Capital Management Ltd., and Citadel Advisors LLC, with", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T10:10:40", "published_display": "17 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Ltd", "summary": "This article provides a detailed revenue breakdown for Zhengye Biotechnology Holding Ltd (ZYBT) for fiscal year 2024. It highlights the company's primary revenue sources, with swine vaccines accounting for the largest proportion at 84.67%, followed by poultry vaccines and other v", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:40", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology receives Nasdaq bid price deficiency notice", "summary": "Zhengye Biotechnology (NASDAQ:ZYBT) has received a notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share, with its stock trading significantly lower. The company has 180 calendar days to regain compliance, potentially considering a reverse sh", "url": "https://m.uk.investing.com/news/stock-market-news/zhengye-biotechnology-receives-nasdaq-bid-price-deficiency-notice-93CH-4714641?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-05T21:39:27", "published_display": "05 Jun 2026 21:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology receives Nasdaq bid price deficiency notice By Investing.com", "summary": "Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) has received a Nasdaq deficiency notice for failing to meet the minimum bid price requirement of $1.00 per share. The company has 180 days to regain compliance by achieving a closing bid price of at least $1.00 for ten consecuti", "url": "https://m.au.investing.com/news/stock-market-news/zhengye-biotechnology-receives-nasdaq-bid-price-deficiency-notice-93CH-4472728?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-05T19:09:51", "published_display": "05 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotech's Nasdaq Lifeline: A 180-Day Race Against Financial Reality", "summary": "Zhengye Biotech (Nasdaq: ZYBT) has received a Nasdaq deficiency notice due to its stock failing to maintain the $1.00 minimum bid price, giving it until November 25, 2026, to regain compliance. The company faces significant financial challenges, including an 87% stock drop, a 37.", "url": "https://briefglance.com/articles/zhengye-biotechs-nasdaq-lifeline-a-180-day-race-against-financial-reality", "source_name": "BriefGlance", "published_at": "2026-06-05T09:11:10", "published_display": "05 Jun 2026 09:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Receives Nasdaq Letter for Minimum Bid Price Deficiency", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/zhengye-biotechnology-receives-nasdaq-letter-205504062.html", "source_name": "MT Newswires", "published_at": "2026-06-04T20:55:04+00:00", "published_display": "04 Jun 2026 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotech has 6 months to lift stock back above $1", "summary": "Zhengye Biotechnology (ZYBT) received a Nasdaq notice on May 29, 2026, for failing to meet the US$1.00 minimum bid price requirement for 30 consecutive business days. The company has until November 25, 2026, to regain compliance by having its stock close at or above US$1.00 for a", "url": "https://www.stocktitan.net/news/ZYBT/zhengye-biotechnology-holding-limited-receives-nasdaq-notification-liify8zbpl9h.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:05:04", "published_display": "04 Jun 2026 20:05", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency", "summary": "Zhengye Biotechnology Holding Limited (ZYBT) announced it received a Nasdaq notification for not meeting the minimum bid price requirement of US$1.00 per share. The company has 180 calendar days, until November 25, 2026, to regain compliance by maintaining a closing bid price of ", "url": "https://sg.finance.yahoo.com/news/zhengye-biotechnology-holding-limited-receives-200500447.html", "source_name": "Market source", "published_at": "2026-06-04T20:05:03", "published_display": "04 Jun 2026 20:05", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Receives Nasdaq Non-Compliance Notification Regarding Minimum Bid Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNQ0UzdlNmWFBZckNzVVI4WXFFWmhXTm1xSWhjbzdDVlBSX0JxRzdNQ0VfWXBZZ0VBaU9mWVJVS3BXUVZZMks2N0ZSb0UzSm80d0dfY1hTbFNrYmtmZkJHN1ZIRklTMUpHMU9IQkJ5ZV9fdklWM0tKcFJhSEVWbjc4MnZybF9zVGxaWEhlRVhjVldsRE1PNFdwOUUtRDd6d2l2QmM2Ui03Y1l3aldfV0lpZDJLaDY4ZlU1TUl6V0FpNkMtZU9UcVd0cWdVQWVNQmFCYjdJQlZYYkpCdw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYBT Stock Price, Quote & Chart | ZHENGYE BIOTECHNOLOGY-A (NASDAQ:ZYBT)", "summary": "This article provides a detailed overview of ZHENGYE BIOTECHNOLOGY-A (NASDAQ: ZYBT) stock, including its current price, performance metrics, and key statistics like market cap and EPS. It also presents ChartMill's technical and fundamental analysis ratings, highlighting the compa", "url": "https://www.chartmill.com/stock/quote/ZYBT/profile", "source_name": "ChartMill", "published_at": "2026-05-17T18:39:02", "published_display": "17 May 2026 18:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "This page provides an overview of Zhengye Biotechnology Holding Ltd (ZYBT) on TradingKey. It details the stock's current price, market cap, and offers sections for financials, discussions, and analysis. The content also highlights TradingKey's various tools, news, and educational", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zybt/comments", "source_name": "TradingKey", "published_at": "2026-05-12T02:39:13", "published_display": "12 May 2026 02:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results", "summary": "Zhengye Biotechnology Holding Limited announced its financial results for fiscal year 2025, reporting a net loss of RMB83.0 million, compared to a net income of RMB13.5 million in 2024. This downturn was primarily due to a challenging hog market and government policies impacting ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zhengye-biotechnology-holding-limited-announces-203000334.html", "source_name": "Market source", "published_at": "2026-04-29T20:10:06", "published_display": "29 Apr 2026 20:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China hog slump hits Zhengye as vaccine maker posts annual loss", "summary": "Zhengye Biotechnology (Nasdaq: ZYBT) announced a 37.6% decrease in total revenue for fiscal year 2025, reaching RMB116.4 million ($16.6 million), and reported a net loss of RMB83.0 million ($11.9 million). This decline was primarily attributed to a downturn in China's hog market ", "url": "https://www.stocktitan.net/news/ZYBT/zhengye-biotechnology-holding-limited-announces-fiscal-year-2025-jlrqrpqnxug3.html", "source_name": "Stock Titan", "published_at": "2026-04-28T20:09:58", "published_display": "28 Apr 2026 20:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYBT Price Today: Zhengye Biotechnology Holding Limited Stock Price, Quote & Chart | MEXC", "summary": "Zhengye Biotechnology Holding Limited (ZYBT) is currently trading at $0.91, down from its previous close of $0.92. The stock has seen a +7.06% return over the past month but a significant -93.57% decline over the last 12 months, indicating weak performance. The company specialize", "url": "https://www.mexc.co/stocks/zybt", "source_name": "MEXC Exchange", "published_at": "2026-04-25T16:10:24", "published_display": "25 Apr 2026 16:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026", "summary": "Zhengye Biotechnology Holding Limited has implemented a dual-class share structure, effective April 7, 2026, introducing Class A and Class B ordinary shares with different voting rights. This restructuring, approved by shareholders, aims to enhance corporate governance and capita", "url": "https://www.quiverquant.com/news/Zhengye+Biotechnology+Holding+Limited+Announces+Implementation+of+Dual-Class+Share+Structure+Effective+April+7%2C+2026", "source_name": "Quiver Quantitative", "published_at": "2026-04-06T13:30:00", "published_display": "06 Apr 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure", "summary": "Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced the implementation of a dual-class share structure, effective April 7, 2026. The new structure introduces Class A ordinary shares with one vote each and Class B ordinary shares with twenty votes each, with Class B sha", "url": "https://www.globenewswire.com/news-release/2026/04/06/3268492/0/en/Zhengye-Biotechnology-Holding-Limited-Announces-Implementation-of-Dual-Class-Share-Structure.html", "source_name": "GlobeNewswire", "published_at": "2026-04-06T13:10:31", "published_display": "06 Apr 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye's new share classes give some holders 20 votes each", "summary": "Zhengye Biotechnology Holding Limited (ZYBT) has implemented a dual-class share structure, effective April 7, 2026, following shareholder approval on March 24, 2026. This reclassifies the authorized capital into 1.9 billion Class A ordinary shares, each carrying one vote, and 100", "url": "https://www.stocktitan.net/news/ZYBT/zhengye-biotechnology-holding-limited-announces-implementation-of-kxejeuix38pk.html", "source_name": "Stock Titan", "published_at": "2026-04-06T13:10:31", "published_display": "06 Apr 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM", "summary": "Zhengye Biotechnology Holding Ltd. (ZYBT) held its Annual General Meeting on March 24, 2026, where shareholders approved significant changes to the company's governance and share structure. These changes involved the election of new directors, re-election of existing ones, a shar", "url": "https://www.tipranks.com/news/company-announcements/zhengye-biotechnology-shareholders-approve-governance-and-share-structure-changes-at-march-24-agm", "source_name": "TipRanks", "published_at": "2026-03-25T10:39:37", "published_display": "25 Mar 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Zhengye Biotechnology (ZYBT.US)$ still hodl some for moon", "summary": "A moomoo Community member, MsNoFomoTrade, shared a post regarding Zhengye Biotechnology (ZYBT.US), indicating they are still holding the stock with an optimistic outlook for future gains. The brief post is part of a discussion within the moomoo community platform.", "url": "https://www.moomoo.com/community/feed/zhengye-biotechnology-zybt-us-still-hodl-for-moon-116278005530630?chain_id=Name1K9-3FXPhg.1l0puc0&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A57%2C%22f%22%3A%22www.moomoo.com%2Fstock%2FDLO-US%22%7D", "source_name": "Moomoo", "published_at": "2026-03-23T15:39:11", "published_display": "23 Mar 2026 15:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Announces Resignation of Wenbin Wang as Independent Director, Member of Committees, and Chairperson of the Compensation Committee, Effective February 18, 2026", "summary": "Zhengye Biotechnology Holding Limited announced that Wenbin Wang resigned as an independent director, a member of the Audit, Compensation, and Nominating and Corporate Governance Committees, and chairperson of the Compensation Committee, effective February 18, 2026. Wang's resign", "url": "https://www.marketscreener.com/news/zhengye-biotechnology-holding-limited-announces-resignation-of-wenbin-wang-as-independent-director-ce7e5cd8d980ff24", "source_name": "www.marketscreener.com", "published_at": "2026-02-24T10:51:40", "published_display": "24 Feb 2026 10:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM", "summary": "Zhengye Biotechnology Holding Ltd. announced that independent director Wenbin Wang resigned on February 18, 2026, due to personal reasons, leaving the company temporarily non-compliant with Nasdaq's majority independent director rule. The company plans to appoint a replacement at", "url": "https://www.tipranks.com/news/company-announcements/zhengye-biotechnology-director-resigns-nasdaq-independence-deficiency-to-be-addressed-at-march-agm", "source_name": "TipRanks", "published_at": "2026-02-23T21:30:11", "published_display": "23 Feb 2026 21:30", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYBT Should I Buy", "summary": "An analysis of Zhengye Biotechnology Holding Ltd (ZYBT) indicates it is not a strong buy for long-term beginner investors. Technical indicators show a bearish trend with weakening momentum and no positive catalysts or significant trading signals. The stock is trading below its pi", "url": "https://intellectia.ai/en/stock/ZYBT/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-02-23T11:51:18", "published_display": "23 Feb 2026 11:51", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Issues 2026 Chairman\u2019s Letter to Shareholders", "summary": "Zhengye Biotechnology Holding Limited's Chairman, Zhenfa Han, issued a letter to shareholders detailing the company's achievements in 2025 and strategic priorities for 2026. The letter highlights R&D innovation, regulatory milestones, international market expansion, enhanced prod", "url": "https://www.globenewswire.com/news-release/2026/02/10/3235307/0/en/Zhengye-Biotechnology-Holding-Limited-Issues-2026-Chairman-s-Letter-to-Shareholders.html", "source_name": "GlobeNewswire", "published_at": "2026-02-10T13:58:26", "published_display": "10 Feb 2026 13:58", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter", "summary": "Zhengye Biotechnology Holding Limited, a veterinary vaccine manufacturer, released a shareholder letter highlighting its 2025 achievements and outlining its strategic plan for 2026. The company reported significant milestones in R&D, regulatory approvals, international market exp", "url": "https://www.quiverquant.com/news/Zhengye+Biotechnology+Holding+Limited+Highlights+2025+Achievements+and+2026+Strategic+Plan+in+Shareholder+Letter", "source_name": "Quiver Quantitative", "published_at": "2026-02-10T13:44:00", "published_display": "10 Feb 2026 13:44", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Sees Large Decline in Short Interest", "summary": "Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) experienced a significant 33.1% decrease in short interest in December, reducing the total shorted shares to 30,788. Several hedge funds, including Jane Street and Invesco, established new positions in the company despite its cu", "url": "https://www.marketbeat.com/instant-alerts/zhengye-biotechnology-holding-limited-nasdaqzybt-sees-large-decline-in-short-interest-2025-12-29/", "source_name": "MarketBeat", "published_at": "2025-12-29T17:08:52", "published_display": "29 Dec 2025 17:08", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) May Have Run Too Fast Too Soon With Recent 26% Price Plummet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSVg1aUU0eGdnYTBQaFRZcEhtdjNKOS1yb0xkVHdnSHpCQ3BzZUlPV2NfeXZrbnQ3X0F4MktFcW0yQzVvbEpscEp5Nm1Mak50VWRZQXpHeGZDOVptdWd3a1drTzFOb2NvNUVjSHN5VjU5QWNwREx4bE1wWk5MNmxvUzlpLXRPRWc0cExVZE4wSG1iYzBkcW5mb0pYOGdOaUREUjZUQndBZnk2SXc?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) 26% Share Price Surge Not Quite Adding Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxNRi1ReDNHVVg5VmNKc1lyR1pXZV9yd1NpUTE4bGdmSGpRQ1AyeFlTUGw5OVlTQkNvNEJBWE01OU5SajRBMnREcTl1UExYSEw3TnM1WHJ4R3JILU4zcmJEWlNvdS1fX0YxV1hpZTZPX0NOZXdwRTZtWlRtT3k3VHBWQW10TnVsT0xabWlXMWhkRDZKZGQ2cU9UTjRKcU93Y0lsNXZxWTJPc1hzck1ZY05idkQtMDhxN1JYUGEybEpwMXhNNzRESURxalFRY3llVTZ0Ym9HT0V5NnZCQW1DX1JJZU5vOXN1SEs1c0hQOHg2akxNSkNwR2fSAfsBQVVfeXFMT0pWbEppeUR3VVJRZXdkdXVDcDRyY2Zpa1ZPOTNfWUtPbm5iMjh2bGdjU1ZWSFM1SzhYZnAta0RXdnFEbUgyaVFlSUZrNG9RWWFTT0xGQW5xSm5MUEdpMDBUTG1ydnVna2RwaW5IYjJpdndxRnRkak5pUklvUmkzOGpiSGpIY0hnLVpUeEppamlkTHBJTnBONU1uTEdteHZCMUpLN3FxN1ZreDVWM1ZqZDZoX1pwRXNKT0w0cGFycmFRVUt2QnpQa0R6WDg0Wkw0RUdOYzc2ZTFzYWtadVhkNUVMYjZNT3JjVWFzaERYNzhOMW9ja1FEYWdOMEU?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zhengye Biotech Earnings: Revenue Falls 12% as Company Pivots to Pet Vaccines with Exclusive Drug Approvals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQUm05LU9FRW5lSEU5WHRlNDV6VWFYSG9XRzA4c2pXczBBRDNfYmcxdy1XRmQ2eGxyRzNOX0xDWEZMSGFBdkl2RnU1NUNGWlI4TG5xYXF5Q3FkWHpTWjR0aXlEOHhWeVFpT052TEVhaU9rLUcyMlhVb0hkSm55RnhUOFNMUmdCeWNaQ2FDNlM0ZlZmd3BlenNLblUyMU1rd1MxaC1MdU9CaTZqVThNN28yQ0dPRWZxeW1McXp3?oc=5", "source_name": "Stock Titan", "published_at": "2025-07-03T07:00:00+00:00", "published_display": "03 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZYBT Stock Price and Chart \u2014 NASDAQ:ZYBT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE84U1k3X0pLUFFLQ250dTVWVjRYclZPT1R3LThaNXY3ZGF5Tm5taGdLNGJpYUFQU2dzZWNQTXBNdl90REZnZkhGYXhJd0dSa3Z5cExQWW5RV1l5TWpS?oc=5", "source_name": "TradingView", "published_at": "2025-01-07T16:38:47+00:00", "published_display": "07 Jan 2025 16:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 62, "total_relevant": 36, "sentiment_summary": {"positive": 6, "negative": 15, "neutral": 15, "score": 43, "total": 36, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 13.75, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 15}, "market_context": {"has_market_context": true, "latest_close": 0.75, "latest_week": "2026-06-19", "one_week_move": -9.7, "four_week_move": -13.7, "twelve_week_move": -11.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.871151, "market_dynamics_buy_signal": false, "relative_strength": -78.611605, "fair_value_gap": -80.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.6922, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.7% over one week, -13.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 10}, {"label": "Stock Titan", "count": 4}, {"label": "Quiver Quantitative", "count": 3}, {"label": "Market source", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "TipRanks", "count": 2}, {"label": "Investing.com UK", "count": 1}, {"label": "Investing.com Australia", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 6}, {"label": "Regulatory and legal", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "43/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.7% over one week, -13.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Zhengye Biotechnology Holding Ltd (ZYBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages"}], "updated_at": "2026-06-23T04:07:32.334467+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}